Status:
COMPLETED
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Lead Sponsor:
Novartis
Conditions:
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Eligibility:
All Genders
50+ years
Phase:
PHASE1
PHASE2
Brief Summary
Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With S...
Detailed Description
The safety and tolerability of single intravitreal injections of ranibizumab was evaluated in patients enrolled in the single dose phase (Group A). Patients who successfully completed the single dose ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Male or female patients 50 years of age or greater
- Patients with primary or recurrent subfoveal CNV secondary to AMD
- Patients who have a BCVA score between 73 and 24 letters in the study eye using ETDRS-like grading charts (approximately 20/40 to 20/320)
- Exclusion Criteria
- 1\. No prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy
- Extension Phase
- Inclusion criteria:
- Personally provided written informed consent to participate in the extension phase.
- Patients with subfoveal CNV secondary to AMD who had completed the multiple dose phase in either of the ranibizumab groups (Group A or B).
- Patients could participate in the extension phase even if they failed to do so on the day of the exit visit in the multiple dose phase (Group A and B), regardless of the time elapsed until the participation in the extension phase.
- Exclusion criteria:
- Received anti-angiogenic drugs (bevacizumab, pegaptanib, ranibizumab, anecortave acetate, corticosteroids or protein kinase C inhibitors, etc.) or
- Participated in any clinical study of an investigational drug other than this one during the period between the exit visit of the multiple dose phase and the start in the extension phase, if they failed to be enrolled into the extension on the day of the exit visit. Patients were to be excluded even when the fellow eye was treated with any of these drugs.
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00284089
Start Date
April 1 2005
End Date
January 1 2009
Last Update
February 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Tokyo, Japan